PEG10 is imperative for TGF-β1-induced epithelial‑mesenchymal transition in hepatocellular carcinoma

Zhang,Minfeng; Sui,Chengjun; Dai,Binghua; Shen,Weifeng; Lu,Jiongjiong; Yang,Jiamei

doi:10.3892/or.2016.5282

PEG10 is imperative for TGF-β1-induced epithelial‑mesenchymal transition in hepatocellular carcinoma

Authors:
- Minfeng Zhang
- Chengjun Sui
- Binghua Dai
- Weifeng Shen
- Jiongjiong Lu
- Jiamei Yang
View Affiliations

Affiliations: Department of Special Medical Care Ⅰ and Liver Transplantation, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, P.R. China
Published online on: November 29, 2016 https://doi.org/10.3892/or.2016.5282
Pages: 510-518

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Substantial evidence indicates that transforming growth factor-beta 1 (TGF-β1) plays a vital role in epithelial-mesenchymal transition (EMT). PEG10 has been shown involved in invasion and metastasis of tumors. The present study investigated the role of PEG10 in TGF-β1-triggered EMT in hepatocellular carcinoma (HCC) progression. Immunohistochemistry and real-time PCR were used to measure the expression level of PEG10 in clinical HCC tissues with or without lymph node metastasis, and normal tissues. The results showed that PEG10 expression is higher in HCC tissues and associated with overall survival (OS) and lymph node metastasis. Moreover, PEG10 expression level was remarkably higher in hepatic cancer cells than the normal hepatic cell line L02. In the present study, we constructed an adenovirus vector containing the coding area of PEG10 (Ad-PEG10) and infected HepG2 cells and found that overexpression of PEG10 promoted the cell migration, invasion ability and EMT of HepG2 cells. TGF-β1 acted on HepG2 cells by enhancing cell migration, invasion, EMT and upregulating PEG10 expression level. However, cells pretreated with adenovirus vector of PEG10 shRNAs (Ad-shRNA1 and Ad-shRNA2) did not occur EMT prior to TGF-β1 stimulation. Moreover, TGF-β1 did not increase the migration and invasion of cells with PEG10 knockdown and overexpression of PEG10 confers chemoresistance to HepG2 cells. Accordingly, sufficient PEG10 expression level is essential for TGF-β1 induced EMT and associated with the chemoresistance in HepG2 cells.

View Figures

View References

1	Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, et al: Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol. 62:363–370. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen WX, Zhang ZG, Ding ZY, Liang HF, Song J, Tan XL, Wu JJ, Li GZ, Zeng Z, Zhang BX, et al: MicroRNA-630 suppresses tumor metastasis through the TGF-β-miR-630-Slug signaling pathway and correlates inversely with poor prognosis in hepatocellular carcinoma. Oncotarget. 7:22674–22686. 2016.PubMed/NCBI
3	Xu MY, Chen R, Yu JX, Liu T, Qu Y and Lu LG: AZGP1 suppresses epithelial-to-mesenchymal transition and hepatic carcinogenesis by blocking TGFβ1-ERK2 pathways. Cancer Lett. 374:241–249. 2016. View Article : Google Scholar : PubMed/NCBI
4	Ferroudj S, Yildiz G, Bouras M, Iscan E, Ekin U and Ozturk M: Role of fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance. Hepatol Res. Feb 16–2016.(Epub ahead of print). doi: 10.1111/hepr.12675. View Article : Google Scholar : PubMed/NCBI
5	Ono R, Kobayashi S, Wagatsuma H, Aisaka K, Kohda T, Kaneko-Ishino T and Ishino F: A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics. 73:232–237. 2001. View Article : Google Scholar : PubMed/NCBI
6	Li CM, Margolin AA, Salas M, Memeo L, Mansukhani M, Hibshoosh H, Szabolcs M, Klinakis A and Tycko B: PEG10 is a c-MYC target gene in cancer cells. Cancer Res. 66:665–672. 2006. View Article : Google Scholar : PubMed/NCBI
7	Bang H, Ha SY, Hwang SH and Park CK: Expression of PEG10 is associated with poor survival and tumor recurrence in hepatocellular carcinoma. Cancer Res Treat. 47:844–852. 2015. View Article : Google Scholar : PubMed/NCBI
8	Deng X, Hu Y, Ding Q, Han R, Guo Q, Qin J, Li J, Xiao R, Tian S, Hu W, et al: PEG10 plays a crucial role in human lung cancer proliferation, progression, prognosis and metastasis. Oncol Rep. 32:2159–2167. 2014.PubMed/NCBI
9	Li X, Xiao R, Tembo K, Hao L, Xiong M, Pan S, Yang X, Yuan W, Xiong J and Zhang Q: PEG10 promotes human breast cancer cell proliferation, migration and invasion. Int J Oncol. 48:1933–1942. 2016.PubMed/NCBI
10	Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, et al: The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep. 12:922–936. 2015. View Article : Google Scholar : PubMed/NCBI
11	Xiong J, Qin J, Zheng Y, Peng X, Luo Y and Meng X: PEG10 promotes the migration of human Burkitts lymphoma cells by up-regulating the expression of matrix metalloproteinase-2 and −9. Clin Invest Med. 35:E117–E125. 2012.PubMed/NCBI
12	Li X, Zheng L, Zhang F, Hu J, Chou J, Liu Y, Xing Y and Xi T: STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer. Oncotarget. 7:23197–23211. 2016.PubMed/NCBI
13	Da C, Liu Y, Zhan Y, Liu K and Wang R: Nobiletin inhibits epithelial-mesenchymal transition of human non-small cell lung cancer cells by antagonizing the TGF-β1/Smad3 signaling pathway. Oncol Rep. 35:2767–2774. 2016.PubMed/NCBI
14	Dong Z, Tai W, Lei W, Wang Y, Li Z and Zhang T: IL-27 inhibits the TGF-β1-induced epithelial-mesenchymal transition in alveolar epithelial cells. BMC Cell Biol. 17:72016. View Article : Google Scholar : PubMed/NCBI
15	Li GC, Ye QH, Dong QZ, Ren N, Jia HL and Qin LX: TGF beta1 and related-Smads contribute to pulmonary metastasis of hepatocellular carcinoma in mice model. J Exp Clin Cancer Res. 31:932010. View Article : Google Scholar
16	Ma H, Gao L, Li S, Qin J, Chen L, Liu X, Xu P, Wang F, Xiao H, Zhou S, et al: CCR7 enhances TGF-β1-induced epithelial-mesenchymal transition and is associated with lymph node metastasis and poor overall survival in gastric cancer. Oncotarget. 6:24348–24360. 2015. View Article : Google Scholar : PubMed/NCBI
17	Yang J, Li T, Gao C, Lv X, Liu K, Song H, Xing Y and Xi T: FOXO1 3UTR functions as a ceRNA in repressing the metastases of breast cancer cells via regulating miRNA activity. FEBS Lett. 588:3218–3224. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zheng L, Li X, Meng X, Chou J, Hu J, Zhang F, Zhang Z, Xing Y, Liu Y and Xi T: Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer. Mol Cell Endocrinol. 427:133–142. 2016. View Article : Google Scholar : PubMed/NCBI
19	Xu T, Zhang J, Chen W, Pan S, Zhi X, Wen L, Zhou Y, Chen BW, Qiu J, Zhang Y, et al: ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition. Cancer Lett. 377:140–148. 2016. View Article : Google Scholar : PubMed/NCBI
20	Liu DC, Yang ZL and Jiang S: Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Pathol Oncol Res. 17:859–866. 2011. View Article : Google Scholar : PubMed/NCBI
21	Peng W, Zhao G, Ma Y, Yu H and Wang X: Dendritic cells transfected with PEG10 recombinant adenovirus elicit anti-tumor immune response in vitro and in vivo. Vaccine. 29:3501–3506. 2011. View Article : Google Scholar : PubMed/NCBI
22	Liu K, Guo L, Guo Y, Zhou B, Li T, Yang H, Yin R and Xi T: AEG-1 3-untranslated region functions as a ceRNA in inducing epithelial-mesenchymal transition of human non-small cell lung cancer by regulating miR-30a activity. Eur J Cell Biol. 94:22–31. 2015. View Article : Google Scholar : PubMed/NCBI
23	Jie X, Lang C, Jian Q, Chaoqun L, Dehua Y, Yi S, Yanping J, Luokun X, Qiuping Z, Hui W, et al: Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. Oncogene. 26:5741–5751. 2007. View Article : Google Scholar : PubMed/NCBI
24	Ip WK, Lai PB, Wong NL, Sy SM, Beheshti B, Squire JA and Wong N: Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma. Cancer Lett. 250:284–291. 2007. View Article : Google Scholar : PubMed/NCBI
25	Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R: Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
26	Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al: Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 527:472–476. 2015. View Article : Google Scholar : PubMed/NCBI
27	Bharti R, Dey G and Mandal M: Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement. Cancer Lett. 375:51–61. 2016. View Article : Google Scholar : PubMed/NCBI
28	Cañadas I, Rojo F, Taus Á, Arpí O, Arumí-Uría M, Pijuan L, Menéndez S, Zazo S, Dómine M, Salido M, et al: Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res. 20:938–950. 2014. View Article : Google Scholar : PubMed/NCBI